Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective
Julie-Anne Tanner1, Paige E Davies1, Christopher C Overall2
1Assurex Health Ltd, a subsidiary of Myriad Neuroscience, Toronto, ON, M5T 1L8, Canada.
Abstract:
Aim: Evaluate the cost-effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcare system perspective. Materials & methods: Clinical and economic data associated with depression were extracted from published literature. Clinical (quality-adjusted life years; QALYs) and economic (incremental cost-effectiveness ratio) outcomes were modeled using combinatorial PGx and TAU treatment strategies across a 5-year time horizon. Results: With the combinatorial PGx strategy to guide treatment, patients were projected to gain 0.14-0.19 QALYs versus TAU. Accounting for test price, combinatorial PGx saved CAD $1,687-$3,056 versus TAU. Incremental cost-effectiveness ratios ranged from -$11,861 to -$16,124/QALY gained. Conclusion: Combinatorial PGx testing was more efficacious and less costly compared with the TAU for depression.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Bioequivalence of Drugs: Drugs with Multiple Indications
Factors Affecting Drug Response: Overview